BioPharma Dive – AI / Data
Helixgate AI & Biotech Collaboration Series + Helixgate Industry Nights
Helixgate AI & Biotech Collaboration Series + Helixgate Industry Nights brings together leaders and professionals from biotechnology, pharma, artificial intelligence, science, technology, medicine and healthcare for an evening of industry insights, networking and collaboration.
Date: October 22, 2026
Location: Del Mar Social, San Diego, California
Reserve your spot and purchase tickets on Eventbrite:
https://www.eventbrite.com/e/helixgate-ai-biotech-collaboration-series-helixgate-industry-nights-tickets-1998469781915?aff=oddtdtcreator
The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine.
Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since 2021 amid several setbacks.
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Tomato Gene SlXTH3 Opens the Door for Devastating Bacterial Wilt Pathogen
Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing – 09/14/2026
Takeda’s Plump, GV’s Yeshwant announce retirement plans
-
Fierce Biotech6 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Endpoints News6 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized6 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Nature Biotechnology6 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Uncategorized4 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized4 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
STAT News – Biotech6 months agoSTAT+: In private meetings, White House works to win pharma companies’ support for drug pricing bill
-
Nature Biotechnology6 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read